Literature DB >> 7548234

Cirrhosis of the human liver: an in vitro 31P nuclear magnetic resonance study.

S D Taylor-Robinson1, E L Thomas, J Sargentoni, C D Marcus, B R Davidson, J D Bell.   

Abstract

Human livers with histologically proven cirrhosis were assessed using in vitro 31P NMR spectroscopy. Spectra were compared with those from histologically normal livers and showed significant elevations in phosphoethanolamine (PE) and phosphocholine (PC) and significant reductions in glycerophosphorylethanolamine (GPE) and glycerophosphorylcholine (GPC). There were no significant differences in spectra from livers with compensated and decompensated cirrhosis. These results help to characterise the alterations in membrane metabolism in cirrhosis of the liver.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7548234     DOI： 10.1016/0925-4439(95)00074-e

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  10 in total

1.  Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models.

Authors:  R Jalan; J Sargentoni; G A Coutts; J D Bell; K Rolles; A K Burroughs; S D Taylor Robinson
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

2.  31P MR spectroscopic imaging detects regenerative changes in human liver stimulated by portal vein embolization.

Authors:  Jing Qi; Amita Shukla-Dave; Yuman Fong; Mithat Gönen; Lawrence H Schwartz; William M Jarnagin; Jason A Koutcher; Kristen L Zakian
Journal:  J Magn Reson Imaging       Date:  2011-08       Impact factor: 4.813

3.  Phosphatidylcholine contributes to in vivo (31)P MRS signal from the human liver.

Authors:  Marek Chmelík; Ladislav Valkovič; Peter Wolf; Wolfgang Bogner; Martin Gajdošík; Emina Halilbasic; Stephan Gruber; Michael Trauner; Michael Krebs; Siegfried Trattnig; Martin Krššák
Journal:  Eur Radiol       Date:  2015-01-11       Impact factor: 5.315

4.  3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C.

Authors:  Chun-Yu Zhang; Qian Zhang; Hui-Mao Zhang; Hai-Shan Yang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

5.  Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease.

Authors:  Bengt Norén; Peter Lundberg; Marcus Ressner; Staffan Wirell; Sven Almer; Orjan Smedby
Journal:  Eur Radiol       Date:  2004-09-03       Impact factor: 5.315

6.  Hepatic 31P MRS in rat models of chronic liver disease: assessing the extent and progression of disease.

Authors:  I R Corbin; R Buist; J Peeling; M Zhang; J Uhanova; G Y Minuk
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

7.  Evidence for altered hepatic gluconeogenesis in patients with cirrhosis using in vivo 31-phosphorus magnetic resonance spectroscopy.

Authors:  K K Changani; R Jalan; I J Cox; M Ala-Korpela; K Bhakoo; S D Taylor-Robinson; J D Bell
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

8.  Glycerophosphocholine and Glycerophosphoethanolamine Are Not the Main Sources of the In Vivo (31)P MRS Phosphodiester Signals from Healthy Fibroglandular Breast Tissue at 7 T.

Authors:  Wybe J M van der Kemp; Bertine L Stehouwer; Jurgen H Runge; Jannie P Wijnen; Aart J Nederveen; Peter R Luijten; Dennis W J Klomp
Journal:  Front Oncol       Date:  2016-02-15       Impact factor: 6.244

Review 9.  Hepatic steatosis and fibrosis: Non-invasive assessment.

Authors:  Rustam N Karanjia; Mary M E Crossey; I Jane Cox; Haddy K S Fye; Ramou Njie; Robert D Goldin; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2016-12-07       Impact factor: 5.742

10.  In vivo and in vitro hepatic phosphorus-31 magnetic resonance spectroscopy and electron microscopy in chronic ductopenic rejection of human liver allografts.

Authors:  S D Taylor-Robinson; J Sargentoni; J D Bell; E L Thomas; C D Marcus; K K Changani; N Saeed; H J Hodgson; B R Davidson; A K Burroughs; K Rolles; C S Foster; I J Cox
Journal:  Gut       Date:  1998-05       Impact factor: 23.059
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.